Traphaco Appoints New CEO for the 2021-2026 Term

According to Decision No. 34/2025/QĐ-HĐQT dated November 5, 2025, this appointment is part of Traphaco’s leadership succession plan, ensuring continuity and the preservation of sustainable values built by generations of Traphaco leaders, while enhancing governance capacity and fostering innovation in the company’s new phase of accelerated growth.

Ms. Dao Thuy Ha officially assumes the position of CEO

Born in 1975, Ms. Dao Thuy Ha holds a Master’s degree in Pharmacy and a Master’s degree in Business Administration. She has devoted nearly 30 years to Traphaco, holding various key positions including Assistant to the CEO, Secretary of the Board of Directors, Marketing Director, and most recently Deputy CEO of Sales & Marketing for the 2021-2026 term.

Earlier, on November 5, 2025, Traphaco’s Board of Directors issued a resolution marking the conclusion of Mr. Tran Tuc Ma’s tenure as CEO, following a long period of dedicated service and outstanding performance.

Board of Directors and Executive Board present flowers in appreciation of Mr. Tran Tuc Ma

Traphaco respectfully acknowledges and extends its sincere gratitude to Mr. Tran Tuc Ma for his wholehearted dedication and remarkable contributions over 15 years as CEO, during which he led the company to continuous growth and solidified Traphaco’s position as a leading pharmaceutical enterprise in Vietnam. The Board of Directors and all Traphaco employees wish him good health, happiness, and continued success on his future journeys.

In recent years, the company’s leadership has jointly implemented a dual development strategy encompassing both Eastern and Western medicine, aiming to strengthen competitiveness and expand market scale. Traphaco has maintained stable growth, with consolidated revenue reaching VND 2,370 billion and post-tax profit of VND 257.3 billion in 2024. In the first nine months of 2025, revenue increased by 8.5% and profit by 8%, surpassing the planned targets.

Alongside maintaining its pioneering position in herbal pharmaceuticals with well-known products such as Hoat Huyet Duong Nao, Boganic, and Tottri, Traphaco has also made significant strides in developing high-quality Western medicines, expanding international technology transfer collaborations with partners such as Daewoong Pharmaceutical (South Korea). By the end of 2025, the company expects to own 17 bioequivalent (BE) drugs, with Western medicine accounting for 40% of total sales.

Traphaco is also a pioneer in developing GACP-WHO–certified herbal material areas across Vietnam, contributing to sustainable livelihoods for local farmers while ensuring a green, clean, and internationally standardized supply chain. With a focus on sustainable development, ESG compliance, and the circular economy, Traphaco actively participates in initiatives of the Vietnam Business Council for Sustainable Development (VBCSD), promoting gender equality and environmental protection.

The company has consistently been honored with prestigious awards such as Vietnam National Brand, National Quality Gold Award, Top 50 Best Listed Companies in Vietnam, Top 10 Vietnam Gold Star Award, Top 10 Sustainable Businesses (CSI), and Top 25 Leading Consumer & Industrial Brands selected by Forbes Vietnam.

These achievements reflect Traphaco’s effective governance, sound strategy, and enduring spirit of innovation, forming a solid foundation for the company’s next growth stage—toward sustainable development, global integration, and reinforcing the value of Vietnamese pharmaceutical brands both domestically and internationally.

The appointment of the new CEO marks an important milestone in Traphaco’s journey of transformation, demonstrating the unity and determination of the Board of Directors, Executive Management, and all employees in the shared mission to maintain its leadership in the pharmaceutical industry, drive sustainable growth, and enhance international competitiveness.